April 5, 2021 07:34 AM EDTUpdated 11:08 AM

Another day, another delay: FDA pushes back a second review for AbbVie's Rinvoq, this time in atopic dermatitis

AbbVie is continuing to look for ways to expand its Rinvoq franchise, betting the drug can be the next big thing once Humira’s patent runs …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

An­oth­er day, an­oth­er de­lay: FDA push­es back a sec­ond re­view for Ab­b­Vie's Rin­voq, this time in atopic der­mati­tis